The European Medicines Agency’s CHMP has recommended approval of Gilead Sciences’ lenacapavir, a twice-yearly injection for preventing HIV infection.

Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological respon ...